- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia
Agitation associated with Alzheimer’s Dementia (AAD) lead to worsening outcomes in an already devastating disease. A patient-centered focus is recommended for a comprehensive treatment plan. In this webinar, the speakers will review the burden of AAD, then discuss current treatment recommendations and unmet needs.
Objectives:
- Review the economic and caregiver burden related to agitation associated with Alzheimer’s Disease (AAD)
- List the currently available treatment recommendations and guidelines for AAD treatment recommendations
- Identify gaps with current treatment options, both pharmacologic and nonpharmacologic
Featuring
W. Clay Jackson, MD, DipTh
Assistant Professor of Clinical Psychiatry & Family Medicine; University of TN College of Medicine
Bryan Archuleta, PharmD (OPDC)
Senior Long-Term Care Medical Science Liaison
Speaker W. Clay Jackson, MD, DipTh is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Bryan Archuleta, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
-
The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities
October 10 12:00 pm to 1:00 pm
Registration
Related Resources
-
Understanding Digital Therapeutics
Infographic April 22, 2024Digital therapeutics (DTx) deliver software-based interventions to patients to treat, manage, or prevent a disease or condition.
-
Understanding MDD Treatments With Neuroplastic Effects
Infographic April 22, 2024Researchers are exploring whether it is possible to leverage neuroplasticity to develop treatments for depression.
-
Understanding Neuroplasticity In Depression
Infographic April 22, 2024The brain is constantly changing! The ability of the brain to create, reorganize, or eliminate connections between neurons (synapses) and change how its circuits are wired is called neuroplasticity.
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: